Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Drug Production in March Down as Much as 65% in 3 Quake-hit Prefectures: Korosho
July 25, 2011
- Rivaroxaban Approved for Prevention of DVT in the US
July 25, 2011
- HPB Issues Notification Aimed at Increasing Efficiency of Clinical Trials
July 25, 2011
- J-CKDI Predicts Dialysis Patients to Decrease after Peak in 2017
July 25, 2011
- BMKK to Take the Offensive with 1st-line CML Treatment Sprycel
July 25, 2011
- Combinational Use of Avastin, Xeloda Approved in Europe: Roche
July 25, 2011
- Tohoku Univ. to Start Clinical Trial for ALS Drug in Japan
July 25, 2011
- Over 11,000 Users Now Registered at Daiichi Sankyo's “Handheld Mother-Child Notebook”Website
July 25, 2011
- Medium-sized Domestic Drugmakers to Accelerate M&As, Entry into Overseas Market: Alan Thomas of IMS Japan
July 25, 2011
- Everolimus Recommended for SEGA by CHMP: Novartis
July 25, 2011
- Sanofi Ties Up with Rib-X for Research of Novel Antibiotics
July 25, 2011
- Over 30% of Schizophrenia Patients Prescribed 3 or More Drugs: Survey
July 25, 2011
- Of 4 Major Drug Wholesalers, Only Medipal to Increase Operating Profits in FY2011: Mizuho
July 25, 2011
- FDA Accepts Application for Dacogen for AML: Eisai
July 25, 2011
- Lyrica Shows Efficacy for Fibromyalgia in PIII in Japan: Pfizer
July 25, 2011
- NBI Expects Surge in Sales of Prazaxa after Lifting of Ban on Long-term Prescription
July 25, 2011
- Shionogi Licenses IPF Treatment Pirfenidone to Ildong of South Korea
July 25, 2011
- EPPV Finds No Safety-related Problems with Rasuritek: sanofi-aventis
July 25, 2011
- Lantus Plus One Mealtime Dose of Apidra Non-inferior to Insulin Aspart: Sanofi
July 25, 2011
- Eisai Obtains Marketing Rights to 2 Drugs from Orion in China
July 25, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…